Streetbeat News

Earnings

CWCO

Consolidated Water Co (NASDAQ:CWCO) is scheduled to release its quarterly earnings report on March 27, 2024, with an expected EPS of $0.44. The company's past performance shows a consistent trend of beating EPS estimates, leading to significant share price increases the following day. Over the last year, CWCO shares have surged 92.43%, indicating strong investor confidence. The upcoming earnings report and guidance will be crucial for future stock performance.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 3:00 pm

PLBY

PLBY Group (NASDAQ:PLBY) is scheduled to release its quarterly earnings report on March 27, 2024, with an estimated EPS of $-0.14. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows a pattern of share price decline following earnings misses, with a significant 25.43% drop after last quarter's miss. PLBY's stock has been trading at $0.95, marking a 51.03% decrease over the last year, indicating a bearish outlook among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 3:00 pm

LE

Lands' End (NASDAQ:LE) is scheduled to release its quarterly earnings report on March 27, 2024, with analysts expecting an EPS of $0.21. The company's past performance shows a mixed record of beating and missing EPS estimates, with significant share price movements following the earnings announcements. Shares of Lands' End were trading at $9.0 as of March 25, with a 52-week performance showing an 8.16% decline. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 3:00 pm

VCEL

Vericel (NASDAQ:VCEL) has been analyzed by 5 analysts in the last three months, showing unanimous bullish sentiment. The average 12-month price target is $51.6, marking a 10.02% increase from the previous target. Analysts from Truist Securities and HC Wainwright & Co. have raised their price targets, reflecting positive expectations for Vericel's performance. The company, a leader in cell therapy products for sports medicine and severe burn care, shows strong financial health with notable revenue growth, high net margin, and effective debt management.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 3:00 pm

CTAS

Cintas Corporation (NASDAQ:CTAS) is set to release its Q3 earnings before the market opens on March 27, 2024. Analysts predict earnings of $3.58 per share, up from $3.14 the previous year, with revenue expected at $2.39 billion. Following better-than-expected Q2 results and raised FY24 guidance, CTAS shares dropped 0.6% to $635.66. Analysts from RBC Capital, Barclays, Truist Securities, Stifel, and JP Morgan have updated their ratings and price targets for CTAS, reflecting optimism about the company's performance.

Portfolio Pulse from Avi Kapoor

March 26, 2024 | 2:58 pm

GM

General Motors (NYSE:GM) has seen a surge in options activity, with a notable bearish positioning by high-rolling investors. Benzinga's options scanner revealed 17 significant trades, showing a split sentiment: 41% bullish and 58% bearish. The trades target a price range of $28.0 to $47.0 for GM over the next 3 months. The company, which regained its U.S. market share leader crown in 2022, is currently trading at $43.67, with an anticipated earnings release in 28 days. Analysts from Piper Sandler and Mizuho have issued ratings with a consensus target price of $46.0.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 2:45 pm

DNUT

MKC

PRAX

TSLA

U.S. stocks were higher on Tuesday, with Tesla Inc (TSLA) seeing a 5.8% surge amid reports of Italy's interest in electric truck production with the company. Other stocks like Krispy Kreme (DNUT), McCormick & Company (MKC), and Praxis Precision Medicines (PRAX) also saw significant gains due to various positive developments.

Portfolio Pulse from Avi Kapoor

March 26, 2024 | 2:36 pm

VKTX

Viking Therapeutics Inc (NASDAQ:VKTX) released results from a Phase 1 trial of VK2735, an oral obesity drug, showing dose-dependent weight reductions and minimal side effects. The company plans to continue dose escalation and initiate a Phase 2 trial in the second half of 2024. VKTX shares surged 20.90% to $83.64.

Portfolio Pulse from Vandana Singh

March 26, 2024 | 2:25 pm

TMC

TMC Metals shares are trading lower following the announcement of their Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:20 pm

GM

GM's CFO announced at the BofA Conference that the company is concentrating efforts on making its electric vehicles (EVs) profitable by 2025.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:18 pm